Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (Pediatric MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
-
Clinical Trial Information
Trial Contact: Parker, Melanie; Armatti, Julie M; Doyle, Katherine M; Frankos, Marie
Trial Phone: 321-843-1036 ; 321-843-5284 ; 3218412008 ; 321-842-8738
-
IRB No: APEC1621F
Protocol Abbrev: APEC1621F
Principal Investigator:
Phase: Drug: Phase II
Age Group: Adult; Pediatric
Secondary Protocol No: APEC1621F
Treatment: Drug: Ensartinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03213652
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with ensartinib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor ALK or ROS1 fusions or that harbor ALK missense mutations.
-
Key Eligibility
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No